Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Allows for more precise and efficient planning and monitoring of cancer treatment.

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3-D segmentation, the process by which anatomical structures in medical images are distinguished from one another—an important step in the precise planning of cancer surgery and radiation treatments.

“Organ- and tumor-specific segmentation is fundamental for proper radiation treatment planning and follow-up in cancer patients,” said Lawrence Schwartz, MD, professor and chair of the Department of Radiology, Columbia University Medical Center, who has extensive experience in both conventional and novel imaging techniques. “Our algorithms have been developed in response to the growing demand for quantitative imaging techniques that provide more accurate organ/tumor delineation and tumor response criteria. At the Computational Image Analysis Laboratory, led by Binsheng Zhao, DSc, professor of clinical radiology, we have incorporated advanced methodologies to address these needs. Columbia is pleased to have established a relationship with Varian, a manufacturer of treatment devices.”

Three-D segmentation of CT and MR images provides a reliable way to identify organs such as the liver, spleen, and kidneys. Determining organ and tumor contours and volumes (including those of primary and metastatic tumors) before, during, and after treatment can be challenging. Accurate and efficient characterization of these diverse structures is necessary to enable noninvasive assessments in clinical practice and clinical trials, as well as in radiation treatment planning.

“Modern radiation treatment planning requires careful delineation of the targeted tissue, as well as the critical structures to be avoided,” said Jeff Amacker, senior director of clinical solutions at Varian. “We hope that our collaborative efforts with Columbia University Medical Center’s radiology department will lead to improved patient care by providing new tools and automation for the precise planning of radiation treatments.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials
One treatment involves skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy.
Friday, December 21, 2012
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!